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Introduction: There is limited evidence documenting
the effectiveness of Advance Care Planning (ACP) in
cancer care. The present randomised trial is designed
to evaluate whether the administration of formal ACP
improves compliance with patients’ end-of-life (EOL)
wishes and patient and family satisfaction with care.
Methods and analysis: A randomised control trial in
eight oncology centres across New South Wales and
Victoria, Australia, is designed to assess the efficacy of
a formal ACP intervention for patients with cancer.
Patients with incurable cancer and an expected survival
of 3–12 months, plus a nominated family member or
friend will be randomised to receive either standard
care or standard care plus a formal ACP intervention.
The project sample size is 210 patient–family/friend
dyads. The primary outcome measure is family/friend-
reported: (1) discussion with the patient about their
EOL wishes and (2) perception that the patient’s EOL
wishes were met. Secondary outcome measures
include: documentation of and compliance with patient
preferences for medical intervention at the EOL; the
family/friend’s perception of the quality of the patient’s
EOL care; the impact of death on surviving family;
patient–family and patient–healthcare provider
communication about EOL care; patient and family/
friend satisfaction with care; quality of life of patient
and family/friend subsequent to trial entry, the patient’s
strength of preferences for quality of life and length of
life; the costs of care subsequent to trial entry and
place of death.
Ethics and dissemination: Ethical approval was
received from the Sydney Local Health District (RPA
Zone) Human Research Ethical Committee, Australia
(Protocol number X13-0064). Study results will be
submitted for publication in peer-reviewed journals and
presented at national and international conferences.
Trial registration number: Pre-results;
ACTRN12613001288718.
INTRODUCTION
End-of-life (EOL) care is a key component of
essential services for people with advanced
cancer.1 Unfortunately, EOL care of patients
with cancer has not kept pace with improve-
ments in treatments directed at the cancer.
While evidence shows that most patients with
cancer prefer to die at home or in a hospice,
hospital remains the most common place of
death.2 3 In a recent study, 65% of 28 000
patients with advanced solid tumours were
found to have received at least one form of
aggressive care within the last 30 days of life.4
Aggressive care in this study was deﬁned as
either hospital admission, an intensive care
unit (ICU) admission or an emergency room
visit, as well as a chemotherapy or radiation
treatment. Apart from the psychoemotional
trauma, such late interventions have signiﬁ-
cant costs for the health system and the
patient and their family.
Advance Care Planning (ACP) refers to
the process by which patients, families and
health professionals discuss and establish
future goals of care in accordance with a
patient’s values and preferences. ACP is
intended to support patients in receiving the
care they would have chosen should they
become too unwell to make their own EOL
decisions near death. There is some evidence
that complex ACP interventions may increase
the frequency of out-of-hospital and
out-of-ICU care and increase compliance
with patients’ EOL wishes.5 However, the fre-
quency of EOL discussions in cancer care is
low6 and limited research has been under-
taken on the impact of complex ACP inter-
ventions in cancer. In a 2014 review of 113
studies on the effects of ACP, only 18% (20
studies) reported on complex ACP interven-
tions and only two of these studies included
patients with cancer.5 Although ACP has the
potential to improve the quality of death for
patients with cancer, the effects of complex
ACP interventions in this population are
unknown. The present trial is designed to
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evaluate whether the administration of a coordinated
ACP intervention improves compliance with patient’s
EOL wishes, patient and family satisfaction with care,
and the experience of death and dying.
OBJECTIVE
The objective of the ACP study is to evaluate the efﬁcacy
of a formal ACP intervention for patients with incurable
cancer who have received systemic therapy (chemother-
apy, targeted therapy or endocrine therapy) and have an
estimated survival of 3–12 months.
We hypothesise that patients randomised to interven-
tion will be more likely to have family/friend report: (1)
discussion with the patient about their EOL wishes and
(2) perception that the patient’s EOL wishes were met.
For secondary outcomes, we hypothesise that patients
participating in the intervention will be more likely to
have their EOL preferences documented and complied
with, have an improved quality of EOL care, have nomi-
nated family or friends who experience less mental ill
health during bereavement, report improved quality of
communication about EOL care, report greater satisfac-
tion with care and value quality over quantity of life
more than patients in the control arm.
We hypothesise that Advance Care Plans will reduce
healthcare costs at the EOL; oncologists’ predictions of
expected survival time will be inaccurate; communica-
tion of expected survival time in terms of typical, best-
case and worse-case scenarios will increase patient
understanding of their prognosis; and that patients and




The ACP trial is a prospective, multisite, randomised
control trial with two parallel groups receiving either
usual care plus a coordinated ACP intervention or usual
care without coordinated ACP. Participants enter the
trial as dyads: a person diagnosed with cancer plus a
nominated family member or friend. After recruitment,
the patient and/or family will be contacted by telephone
at 8-week and then 3-month intervals until the patient’s
death. Family members or friends will be contacted
3 months after bereavement to complete ﬁnal question-
naires. Following the patient’s death, a review of their
medical record will assess documentation of EOL prefer-
ences and medical interventions received in the ﬁnal
2 weeks of life.
The primary outcome measure is family or
friend-reported: (1) discussion with the patient about
their EOL wishes and (2) perception that the patient’s
EOL wishes were met.
The study is planned for a 3-year duration with a
maximum 12-month follow-up period for patients and a
maximum 15-month follow-up period for nominated
family members or friends. The study is registered on
the Australia and New Zealand Clinical Trials Registry
ACTRN12613001288718.
Participants
To be eligible for the ACP study, patients must be
18 years or older, have a diagnosis of incurable cancer,
have received systematic therapy to treat their cancer
and have an expected survival time of 3–12 months.
They must also be able to nominate a family member or
friend who is willing to participate in the trial with
them. All participants must be able to read and write
English, and be capable of reading an information
booklet and completing a series of questionnaires.
Patients are excluded from the trial if they have previ-
ously completed formal ACP.
A total of seven oncology departments across two
Australian states are actively recruiting to the trial: two
oncology units in Melbourne (Austin and Box Hill
Hospitals) and ﬁve in Sydney (The Chris O’Brien Life
house, Campbelltown Hospital, Concord Repatriation
General Hospital, The Royal North Shore Hospital and
the Northern Cancer Institute).
Intervention
Participants in the trial randomised to the intervention
receive nurse-led (ACP clinician) ACP. Patients in the
intervention group will be offered optional information
about their likely life expectancy as part of the ACP
intervention. Experienced oncology nurses or allied
health professionals participate in a two-part training
course and peer mentoring and shadowing in the clin-
ical environment to learn to deliver the study interven-
tion. The intervention is based on the Respecting
Patient Choices model7 with the addition of skills in
EOL communication, and estimating and communicat-
ing typical, best-case and worst-case scenarios for sur-
vival. Treating oncologists will liaise with the ACP
clinician to ensure patients understand their illness,
treatment options and likely prognosis, and will be asked
to sign any Advance Care Plans completed by the
patient. The intervention is speciﬁcally targeted at
patients with advanced cancer with input from the inves-
tigator team, including oncologists and palliative care
physicians.
ACP clinicians complete Part 1 e-Learning Respecting
Patient Choices education course to provide a broad
introduction to ACP, and Part 2 Practical workshop at
Austin Hospital, Australia, based on the Respecting
Patient Choices education course.7 ACP clinicians attend
a focused 1-day workshop to learn additional skills in
EOL communication and in delivering prognostic infor-
mation. The workshop includes cancer-speciﬁc clinical
information and role play with professional actors. Core
components of the intervention are outlined in ﬁgure 1.
The ACP meeting occurs within 2 weeks of enrolment
into the study and includes the patient and their nomi-
nated family or friend. Patients are instructed that
should their goals and wishes change at any stage, they
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should contact their ACP nurse to arrange another
meeting. All ACP meetings are audiotaped for quality
and training purposes. Meetings will be audited to assess
adherence and quality.
Data collection and follow-up
Patients are assessed at baseline, 8 weeks (6 weeks post
intervention), then every 3 months until death or the
end of the study. Nominated family or friends are
assessed at baseline, 8 weeks, every 3 months until the
patient’s death and at 3 months after the patient’s death.
Figure 2 shows a schema of work ﬂow throughout the
study. The assessment schedule for patients and family/
friends are summarised in table 1 and table 2. Following
the patient’s death, a review of their medical record will
assess documentation of EOL preferences and medical
interventions received in the ﬁnal 2 weeks of life.
Study data will be collected and managed using
Research Electronic Data Capture (REDCap) tools
hosted at The University of Sydney. REDCap is a secure,
web-based application designed to support data capture
for research studies.8
Primary outcome
There are no validated or ‘gold-standard’ procedures for
measurement of compliance between patient’s EOL
wishes and the care provided.9 To determine the extent
to which the patient’s EOL wishes were met, we will use
family perception that the patients EOL wishes were
met.
For the primary outcome of this study, we will assess
family/friend-reported: (1) discussion with the patient
about their EOL wishes and (2) perception that the
patient’s EOL wishes were met, assessed at 3 months
after bereavement. Speciﬁcally, family/friends will be
asked:
▸ ‘Did the patient discuss with you any particular
wishes he/she had about the care they would want to
receive if they were dying?’ Answers will be recorded
on a 5-point Likert Scale from 0=‘Not at all’ to
5=‘Very much’.
▸ ‘I am satisﬁed that at the end of his/her life their
wishes were met’. Answers will be recorded on a
5-point Likert Scale from 0 ‘Strongly disagree’ to
5=‘Strongly agree’.
Agreement that EOL wishes were discussed (responses
of ‘Quite a bit’ and ‘Very much’) AND that the patients
EOL wishes were met (responses of ‘Agree’ or ‘Strongly
agree’) will be scored as a positive outcome (ie, wishes
known and complied with).
Secondary outcomes
A. The documentation of patient preferences for EOL care and
concordance with care received at the EOL.
Medical record review will assess concordance between
documentation of preferences for care deﬁned in the lit-
erature as important EOL care goals,10–12 and medical
interventions received in the last 2 weeks of life. As pub-
lished papers used varied time frames (from a few days
to a month) to assess medical interventions received at
the EOL, we adopted a 2-week time point. We will iden-
tify documented patient preferences for place of death,
cardiopulmonary resuscitation, ICU admission and any
other signiﬁcant intervention identiﬁed in a patient’s
medical record, including chemotherapy use within the
last 4 weeks of life. Documented preferences will be
compared with the care received in the last 2 weeks of
life. Documentation of preferences and concordance
Figure 1 Core components of
the Advance Care Planning
(ACP) intervention.
Johnson S, et al. BMJ Open 2016;6:e012387. doi:10.1136/bmjopen-2016-012387 3
Open Access
group.bmj.com on December 11, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
between preferences and care received are required to
receive a positive score. Items will be scored individually.
B. Prevalence, timing and location of EOL care documents.
Medical record review will assess the prevalence, timing
and location of EOL care documents, as well as the
documentation of substitute decision makers, at the hos-
pital where patients received their oncology care.
C. Place of death will be veriﬁed with the caregiver at the
3-month bereavement interview by asking the nomi-
nated family or friends ‘Where did your loved one
die?’
D. Quality of EOL care will be measured using a study-
speciﬁc 27-item tool assessing the family/friend’s sat-
isfaction with the quality of a patient’s death. The
Assessment will be completed via an interview with
the family/friend at 3 months after bereavement and
includes items adapted from Detering et al13 and
Engelberg et al14 Quality about EOL Communication
(QOC). For example, family/friends will be asked,
‘In your opinion, how would you rate the overall
quality of the patient’s death/last week of life?’ And
‘How satisﬁed were you with the way in which the
patient died?’
E. The impact of death on surviving family members will be
measured using the Impact of Events Scale (IES)15 at
3 months after bereavement. This is a validated
15-item tool that identiﬁes risk of developing post-
traumatic stress disorder. In addition, the well-
validated and widely accepted 14-item Hospital
Anxiety and Depression Scale (HADS)16 will be used
Figure 2 Participant assessment and follow-up plan.
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at baseline, every 3 months until the patient’s death
and 3 months after bereavement.
F. Patient–family and patient–healthcare provider communica-
tion about EOL care will be assessed using items
adapted from Wright et al.12
G. Patient and caregiver satisfaction with care will be
assessed using a ﬁve-question survey used in a previ-
ous trial13 focusing on satisfaction with information
provision.
H. Quality of life (QOL) will be measured using the
EQ-5D-5L17 for patients and the 12-item Short-Form
Health Survey (SF-12)18 for caregivers. QOL scores will
be compared between groups and in the same group
at different time intervals. Multivariate relationships
between patients’ QOL and different outcomes of the
intervention will also be examined.
I. Patients’ strength of preferences for QOL and length of
future life will be assessed using a Discrete Choice
Experiment (DCE).19 Patients are presented with a
short description of a health state then asked to
compare two descriptions and select which repre-
sents the better or more desired situation.
J. The cost of ACP and the costs of healthcare used (for
3 months prior to trial entry until death) will be
assessed. Costs of care will be assessed by data linkage
using Commonwealth Medicare and Pharmaceutical
Beneﬁts Scheme (PBS) records, state-based records
on hospital admissions and emergency department
visits, as well as patient-reported out of pocket
expenses and healthcare use of services and products
that are beyond the scope of the administrative data
sets. To determine the wider ramiﬁcations of the
intervention, healthcare-use cost of the nominated
family member or friend will also be obtained before
and after the patient’s death.
K. Accuracy of predictions of life expectancy will be assessed
by comparing the oncologist’s estimate of each
patient’s life expectancy at baseline with the patient’s
Table 1 Patient assessment schedule





Demographics Demographic questionnaire ✓









Quality of life EQ-5D5L ✓ ✓ ✓ ✓
Preference for quantity or quality of
life
Discrete choice experiment ✓ ✓
Patient satisfaction with care Satisfaction with care survey ✓
Costs of ACP Costs of care survey ✓ ✓ ✓




The documentation of patient
preferences for EOL care and
concordance with care received at the
EOL
Medical record review form ✓
Prevalence, timing and location of
EOL care documents
Medical record review form ✓
Table 2 Family/friend assessment schedule





Demographics Demographic questionnaire ✓
Quality of life SF-12 ✓ ✓ ✓ ✓ ✓
Bereavement adjustment Hospital Anxiety and
Depression Scale
✓ ✓ ✓ ✓ ✓
The impact of death on
surviving family members
Impact of Event Scale ✓ ✓




Johnson S, et al. BMJ Open 2016;6:e012387. doi:10.1136/bmjopen-2016-012387 5
Open Access
group.bmj.com on December 11, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
observed survival time using methods developed in a
previous study.20
L. Patient understanding of life expectancy will be assessed
at baseline and at 8 weeks using an instrument devel-
oped in a previous study.21 22 Patients in the interven-
tion group who want information on life expectancy
will be provided with individualised estimates of
worst-case, typical and best-case scenarios for survival
using the oncologist’s estimate and a web-based tool
(iTool) developed by Kiely et al.22
M. Patient and family satisfaction with the ACP intervention
will be assessed using a study-developed
questionnaire.
Box 1 Provides further details on the medical record
review, data collection and assessment of intervention
ﬁdelity.
Sample size
In a previous trial by the investigator group, EOL wishes
were known and respected in 86% of the intervention
group compared with 30% of controls.13 Assuming the
same baseline rate of EOL wishes known and respected
in patients with cancer, and believing a doubling to 60%
would inﬂuence clinical practice, two study groups that
each include 56 patients who die within the 3-year
follow-up period will result in the study having 90%
power to detect a between-group difference with 95%
certainty. A conservative estimate of mortality is 75%. To
allow for incomplete data on 20% of patients and a
further 10% of their nominated family members or
friends, we propose a sample size of 210 patients with
advanced incurable cancer.
Recruitment and randomisation
Oncologists at participating sites will be asked to identify
patients who meet the study inclusion criteria and to
inform patients about the study during their outpatient
oncology visits. Potential participants will be introduced
to a research team member in attendance at the clinic
who will provide them with further details of the study.
Family members or friends who are not in attendance at
the clinic will receive a follow-up phone call from the
research team. The information provided in the consent
form will be the same for the intervention group and
the control group. The information sheets will exclude
naming the intervention (ACP) in order to avoid con-
tamination of the control arm. Participants will be
informed that the project is evaluating the effectiveness
of a programme aimed at improving communication
with patients with advanced cancer, their family and
friends and their doctors. Participants will be informed
that those randomised to the intervention group will
meet with a specially trained nurse to talk through their
goals, wishes and needs for care, now and in the future.
Participants in this study will be advised before entry
that participation is voluntary and they are free to with-
draw at any time.
Participants will be randomised by minimisation with a
1:1 allocation of control group to intervention group.
Participants will be stratiﬁed by site and sex, using the
24/7 Interactive Voice Response System (IVRS)
telephone-based randomisation system at the National
Health and Medical Research Council (NHMRC)
Clinical Trials Centre.
The statistical analysis and preparation of tables and
graphs for the report of the study by the statistician of
the study will be blinded. Research staff completing
follow-up assessment and medical record review will be
blinded to the extent possible (participants will be iden-
tiﬁable by study ID only, but the 8-week assessment con-
tains additional ‘satisfaction with the intervention’
questionnaire for intervention participants and the
medical record may include study-speciﬁc documents).
Participants and oncologists will be non-blinded.
Statistical analysis
The study statistician performing the analysis will be
blinded to group allocation. The effect of the ACP
intervention will be assessed by using χ2 tests for cat-
egorical outcomes and t-tests for continuous outcomes,
if measured at one time point only and if there is no
oncologist effect. Clustering by oncologist will be tested
using mixed models, and if the intracluster correlation
is estimated to be non-zero, outcomes will be analysed
using mixed models and generalised linear mixed
models with oncologist included as a random effect.
Box 1 Details of assessment of the medical record review
and intervention fidelity
Medical record review for deceased patients
Trained members of the research team will consider all of a
patient’s available medical records (at the acute hospital where
they receive their oncology care) to assess concordance between
documentation of preferences for care and medical interventions
received, place of death and timing and location of documentation
of end-of-life (EOL) preferences (secondary outcomes A, B and
C). Reviewers will receive 2 days of face-to-face group training,
and be provided with a standard form and written guidelines. Ten
per cent of records will be reabstracted by a second reviewer to
assess for inter-rater reliability. Reviewers will have real-time con-
sultation with medically trained staff if required. Where the
abstractor is unsure of how to score, cases will be referred first
to the study coordinator and then to the steering committee for
additional review until consensus is reached.
Intervention fidelity
All intervention sessions will be audio recorded. This provides an
opportunity to assess how the intervention was actually delivered
in practice. There are currently no tools available which aim to
measure the quality and consistency of Advance Care Planning
(ACP) interventions. Additionally, there have been no published
reports of auditing actual practice of ACP inside of a clinical trial
setting. We will use the data from the recorded ACP conversations
to: (1) design and evaluate a fidelity instrument, (2) describe var-
iations in ACP intervention delivery and (3) analyse correlations
between delivery and patient outcomes.
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Outcomes which are measured repeatedly (eg, QOL)
will be analysed with mixed models to assess patterns
over time as well as differences between groups at spe-
ciﬁc time points. These models are valid for data that
are missing completely and missing at random.23 All
analyses will follow the intention to treat. Mixed models
are consistent with an intention to treat analysis in the
presence of missing data.24 A secondary per-protocol
analysis will be performed along with an exploration of
why any participants did not receive the treatment to
which they were assigned. Accuracy of predictions of
survival time will be investigated using descriptive statis-
tics and Bland-Altman plots25 for those patients who die
within the follow-up period. Differences in survival will
be explored with Kaplan-Meier plots.
Descriptive statistics will be used to describe the
sample and to compare the characteristics of patients in
the different groups.
Interim analyses plan
Analysis of satisfaction with intervention and QOL data
will be undertaken at midpoint of the study to ensure
no adverse consequences.
Data-monitoring plan
The study steering committee will monitor the course of
the trial and provide ongoing oversight of the prelimin-
ary results. Investigators will review un-blinded results
and, if necessary, will give a recommendation for discon-
tinuation, modiﬁcation or continuation of the study.
DISCUSSION
The study has several strengths and limitations which are
described as follows.
Strengths
The study design follows that of a previous randomised
controlled trial conducted by members of the investiga-
tor team.13 Therefore, the study protocol and interven-
tion have been proven to be feasible and successful in a
different patient population. Furthermore, the ACP
intervention used in the present study has a number of
speciﬁc strengths. First, it includes patients and their
family member or friend. Second, the ACP intervention
is available to participants assigned to intervention for as
many sessions as they request. Third, the ACP interven-
tion has been adapted to be cancer-speciﬁc and ﬁnally,
the intervention includes optional provision of and dis-
cussion of prognostic information. The study also has
methodological strengths. The ACP study is a rando-
mised controlled trial with allocation concealed using a
computer-generated interactive voice system in order to
prevent systematic bias.
Limitations
The proportion of eligible patients who participate in
the trial will be documented. It is likely that there will
be systematic differences between those who choose to
participate in the ACP trial and those who choose not
to participate. Second, it is likely that completing study
questionnaires will prompt some participants in both
arms of the study to consider and discuss their EOL
wishes. Third, it is unavoidable that in conducting a lon-
gitudinal study involving patients with incurable disease,
a number of participants will die before follow-up data
can be collected, withdraw from the study or be lost to
follow-up. Fourth, the study intervention is complex and
requires skill, time and resources to deliver. It may be
difﬁcult to replicate consistently across institutions.
Finally, as the ACP intervention requires the involve-
ment of treating oncologists and documentation in the
medical record, the oncologists and researchers
working in the study cannot be blinded to group
allocation.
Two other randomised controlled trials are underway,
which also investigate the effects of ACP in cancer.26 27
This presents an opportunity for meta-analysis of data
on the effectiveness of ACP in cancer care. Data will
be collected for almost 2000 patients with advanced
cancer across Europe, the USA and Australia. Shared
patient outcomes across all three studies include: con-
cordance with EOL wishes and care received, quality
of communication, quality of death/quality of EOL
care, patient mental health outcomes and acceptability
of the ACP intervention. Further details of each study
are presented in table 3. However, there are no gold-
standard outcomes, or measures to assess the efﬁcacy
of ACP, and a variety of measures will be used across
studies to assess similar outcomes. This presents a
challenge to meta-analysis. Table 3 presents details of
study design, sample size, population, intervention
and primary outcome measure for each study. Shared
patient outcomes and a brief description of the
distinguishing features between studies are also pre-
sented. A full list of the outcome measures used in
each study can be found in the published study
protocols.26 27
ETHICS AND DISSEMINATION
This study is funded by the National Health and Medical
Research (NHMRC) (grant number APP1050596) and
is administered through the University of Sydney. There
are no contractual agreements that limit data access for
investigators. The study sponsor will have no role in the
study design; collection, management and interpretation
of data; writing of reports; and the decision to submit
reports for publication.
The study will be conducted in accordance with the
NHMRC’s guidelines for the ethical conduct of human
research. The study investigator team, which includes
academics and clinicians with a broad range of skills and
experience, has been established as a steering commit-
tee. The steering committee meet quarterly and will
guide study procedures and dissemination of results.
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Important protocol modiﬁcations (eg, changes to eligi-
bility criteria, outcomes, analyses) will be communicated
to relevant parties via regular study newsletters. The
steering committee will also be responsible for assessing,
reporting and managing solicited and spontaneously
reported adverse events and other unintended effects of
trial interventions or trial conduct.
All information collected during the course of the
study will be kept strictly conﬁdential and any informa-
tion which would allow individual participants to be
identiﬁed will not be released. Anonymised data will be
compared; individual patients, family members or oncol-
ogists will not be identiﬁable. The results will be submit-
ted for publication in peer-reviewed journals and will be
presented at national and international conferences.
The results of this study will provide evidence for the dir-
ection and development of quality EOL care for patients
with advanced cancer.
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